www.easy-to-use-pharmacy.com
- US Toll free:
- Regular US:
- UK:
- Categories list
-
- Alcoholism
- Alzheimer's And Parkinson's
- Analgesics
- Anti-inflammatories
- Antiallergic
- Antibiotics
- Anticonvulsants
- Antidepressants
- Antifungals
- Antiparasitic
- Antivirals
- Arthritis
- Asthma
- Birth Control
- Cancer
- Cardiovascular Diseases
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Care
- Gastrointestinal Tract
- HIV
- Hypertension
- Men's Health
- Mental Disorders
- Migraine
- Muscle Relaxants
- Neurological Disorders
- Obesity
- Osteoporosis
- Respiratory Tract
- Skin Care
- Stop Smoking
- Surgery
- Urinary Tract
- Women's Health
Generic Fenofibrate - Tricor
Generic Tricor
Generic Tricor is used for controlling high cholesterol and triglyceride levels in the blood. It is used in combination with a diet low in cholesterol and saturated fat. Generic Tricor is a lipid-lowering agent. It lowers elevated blood triglyceride levels by making the liver produce fewer triglycerides and increasing the elimination of triglycerides from the blood stream.
$1.25
Buy now!
Choose Your language:
- Testimonials
-
Hi Thanks,
Read more »
the order arrived last week no problems, the effect well....... very busy now with my girlfriends. - Thanks
-
- Treatment of chronic hemodialysis patients with low-dose fenofibrate ... - 7thSpace Interactive (press release)
- Treatment of chronic hemodialysis patients with low-dose fenofibrate
- FDA inspectors cite problems at Impax California plant - FiercePharma Manufacturing
- FDA inspectors cite problems at Impax California plantFiercePharma ManufacturingLast year's warning letter followed a wholesale-level recall of 5 lots of 200-mg fenofibrate capsules
- Expect strong growth from US in FY13-14 - Moneycontrol.com
- Expect strong growth from US in FY13-14Moneycontrol
- Santarus' CEO Presents at Bank of America Merrill Lynch 2012 Health Care ... - Seeking Alpha
- Santarus' CEO Presents at Bank of America Merrill Lynch 2012 Health Care
- Santarus Reports First Quarter 2012 Financial Results - MarketWatch (press release)
- Santarus Reports First Quarter 2012 Financial ResultsMarketWatch (press release)FENOGLIDE(fenofibrate) tablets new prescriptions grew 17% and total prescriptions increased 11% for the four-week period ending April 20, 2012, compared with the four-week period ending February 3, 2012, which was just prior to Santarus' initiation of
 |
Bookmark this site |
|---|
 |
Subscribe to the News |
|---|
